The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss
about
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility lociOsteoimmunology: interactions of the bone and immune systemOsteoporosis, inflammation and ageingA review of denosumab for the treatment of osteoporosisRecognizing and treating secondary osteoporosisLow bone mass in microscopic colitis.Postprandial response of bone turnover markers in patients with Crohn's disease.Osteoporosis in inflammatory bowel diseaseBasic and clinical aspects of osteoporosis in inflammatory bowel disease.Vertebral fractures in patients with inflammatory bowel disease compared with a healthy population: a prospective case-control studyAdvances in the understanding of mineral and bone metabolism in inflammatory bowel diseasesDecreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease.Skeletal health of children and adolescents with inflammatory bowel disease.The anti-inflammatory role of vitamin e in prevention of osteoporosis.The intestinal microbiome and skeletal fitness: Connecting bugs and bonesBone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases.Clcn5 knockout mice exhibit novel immunomodulatory effects and are more susceptible to dextran sulfate sodium-induced colitis.Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis.Nigella sativa: A Potential Antiosteoporotic AgentThe role of the immune system in the pathophysiology of osteoporosis.The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism.Prevention and treatment of osteoporosis in inflammatory bowel disease.The early onset of disease may be a risk factor for decreased bone mineral density in patients with inflammatory bowel disease.Age and motor score predict osteoprotegerin level in chronic spinal cord injury.Relationship between Serum Levels of OPG and TGF- β with Decreasing Rate of BMD in Native Chinese Women.Exercise and Crohn's disease: speculations on potential benefits.Osteoprotegerin, s-RANKL, and selected interleukins in the pathology of bone metabolism in patients with Crohn's disease.Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance.Vitamin D status in gastrointestinal and liver disease.Altered bone metabolism in inflammatory disease: role for nutrition.Bone Metabolism and the c.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease.Musculoskeletal manifestations of inflammatory bowel disease.A novel distal enhancer mediates cytokine induction of mouse RANKl gene expression.RANKL inhibition for the management of patients with benign metabolic bone disorders.Bone, inflammation, and inflammatory bowel disease.Immunology and bone.Paediatric inflammatory bowel disease: a mechanistic approach to investigate exclusive enteral nutrition treatment.Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease.Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study.Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma.
P2860
Q24618592-E66BE7FD-63BE-4058-8D98-80346FEBBB68Q24655113-68B4E820-43E2-466B-B1B1-48194D46C13FQ24815520-6F455904-C424-4461-879B-44B0991DEE65Q27005894-B03DB310-99B2-4F01-AB49-02AA20DEDBADQ28270738-0CC84494-44BD-48A5-A3FE-9A394F7F3554Q33905976-C080027C-23A2-44EE-B138-DA3FAE45B683Q33948406-AFC70F61-1771-4A65-B817-074399F2BD32Q33951441-3DC0D068-577E-4B4E-8B5B-5671637EB610Q34225188-66C07A8D-2B85-46DB-B110-5D7B59E999EEQ34268491-80CEC603-C892-465B-98C3-5B6DA4BD02D8Q34597741-E6A107AC-A6F1-4BD8-846D-AACED7314F8CQ34791372-0A041283-AEEC-40C1-AA1B-68662586553EQ35065044-6F1784A6-F726-4D92-8650-1980C3FFB9F5Q35580008-4F603044-3A21-4B11-859D-6C470335FE66Q35594858-D66AF8E2-C19E-4585-B70C-5A7066C2736AQ35614331-7B249675-5A92-4A0E-9538-FF414E35F585Q35702593-82E47901-0A73-4AA9-B0B7-C71B0BF07CC1Q36134061-B4670953-E73E-4FF2-8229-51EA645EFC58Q36225602-362FF106-4325-4C17-B48F-5479478DFE6DQ36324969-C916DA48-394E-4494-9100-313944D1FE1FQ36494408-5C66928A-4C4B-4B58-83B9-5D61E7DDCF0BQ36569260-B936735B-6CB5-45F6-B642-0321F911F885Q36609666-B986BCF0-A14D-4E25-94B1-D6C526A1A681Q36628354-C2D79D95-7DFA-4400-933F-94888F627B50Q36634504-0193C7DF-A3E2-4C83-AD0A-3F2A461E1D32Q36635099-0D04AE65-B9A0-4D5C-BB9B-B66E5FAC0714Q36747140-182ADB7B-7F02-41A2-B66C-BADC246844F7Q36809886-F3CE1EF3-7C6E-468D-A936-2A7462833B35Q37095126-6A9BACF3-A17E-419E-BF2F-C786DD0DBD15Q37138659-699F7510-B361-4CFC-8BF5-F0AB55D9B151Q37396629-C2A44595-9F06-443F-8EDC-6C3A9F8B4377Q37466458-5240C3C5-A556-4015-BAAD-572975AC3D8FQ37484556-CE36EA1C-F156-49A2-8ABB-D7478C5B66B8Q37532561-4B062325-3CAC-4E90-B289-A7794B9CEFFCQ37936285-AB84AEEE-665F-4AFF-8ACF-BD60EFC7C756Q38113210-84AA175B-6714-448F-8F36-F9B81B17356BQ38223408-611A2EF8-4F3D-423B-9FA4-2CB917440B70Q38681986-FA6EFE66-AC14-477B-BB7A-B1FC81A49339Q38693577-6B0CDFEB-97A7-454F-9783-5B7A0A2173F7Q38741874-2FBFF841-E00C-4EBD-8738-C893AF48536E
P2860
The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The RANKL/OPG system is activa ...... ates to the state of bone loss
@ast
The RANKL/OPG system is activa ...... ates to the state of bone loss
@en
type
label
The RANKL/OPG system is activa ...... ates to the state of bone loss
@ast
The RANKL/OPG system is activa ...... ates to the state of bone loss
@en
prefLabel
The RANKL/OPG system is activa ...... ates to the state of bone loss
@ast
The RANKL/OPG system is activa ...... ates to the state of bone loss
@en
P2093
P2860
P356
P1433
P1476
The RANKL/OPG system is activa ...... ates to the state of bone loss
@en
P2093
Ludwiczek O
P2860
P304
P356
10.1136/GUT.2004.044370
P407
P577
2005-04-01T00:00:00Z